896722-50-2

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine, 6-chloro-1-(phenylsulfonyl)-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine, 6-chloro-1-(phenylsulfonyl)-;6-chloro-1-(phenylsulfonyl)-1H-Pyrrolo[2,3-b]pyridine;1-(Phenylsulphonyl)-6-chloro-7-azaindole;1-(phenylsulfonyl)-6-chloro-7-azaindole
• CAS NO: 896722-50-2
• Molecular Formula: C₁₃H₉ClN₂O₂S
• Molecular Weight: 292.74
• Mol File: 896722-50-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 136.4 °C
• Boiling Point: 488.6°C at 760 mmHg
• Flash Point: 249.3°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 1.07E-09mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -0.78±0.30(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine, 6-chloro-1-(phenylsulfonyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine, 6-chloro-1-(phenylsulfonyl)-(896722-50-2)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine, 6-chloro-1-(phenylsulfonyl)-(896722-50-2)

Safety Data

• Hazardous Substances Data: 896722-50-2(Hazardous Substances Data)

Usage

General Description

1H-Pyrrolo[2,3-b]pyridine, 6-chloro-1-(phenylsulfonyl)- is a chemical compound that belongs to the pyrrolopyridine class. It consists of a pyridine ring fused to a pyrrole ring, with a chlorine atom and a phenylsulfonyl group attached to it. 1H-Pyrrolo[2,3-b]pyridine, 6-chloro-1-(phenylsulfonyl)- has potential biological and pharmacological activities, and is used in scientific research and drug development. It may have applications in the treatment of various diseases and conditions, and its properties and behavior in different environments are of interest to chemists and researchers.

InChI:InChI=1/C13H9ClN2O2S/c14-12-7-6-10-8-9-16(13(10)15-12)19(17,18)11-4-2-1-3-5-11/h1-9H

Upstream product

• 98-11-3 benzenesulfonic acid 
• 55052-27-2 6-chloro-7-azaindole 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 143468-07-9 6-Chloro-1-methoxycarbonyl-1H-pyrrolo<2,3-b>pyridine 
• 271-63-6 7-Azaindole 
• 98-09-9 benzenesulfonyl chloride 

Downstream Products

• 824-51-1 6-methyl-1H-pyrrolo<2,3-b>pyridine 
• 1399849-64-9 1-(6-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone 
• 896722-51-3 1-benzenesulfonyl-6-methyl-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS

Disclosed are N-(phenyl)-lH-indole-3-sulfonamide and N-(phenyl) -1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related

Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors

Multiple lines of evidence have indicated that pyruvate kinase M2 (PKM2) is upregulated in most cancer cells and it is increasingly recognized as a potential therapeutic target in oncology. In a continuation of our discovery of lead compound 5 and SAR study, the 7-azaindole moiety in compound 5 was systematically optimized. The results showed that compound 6f, which has a difluoroethyl substitution on the 7-azaindole ring, exhibited high PKM2 activation potency and anti-proliferation activities on A375 cell lines. In a xenograft mouse model, oral administration of compound 6f led to significant tumor regression without obvious toxicity. Further mechanistic studies revealed that 6f could influence the translocation of PKM2 into nucleus, as well as induction of apoptosis and autophagy of A375 cells. More importantly, compound 6f significantly inhibited migration of A375 cells in a concentration-dependent manner. Collectively, 6f may serve as a lead compound in the development of potent PKM2 activators for cancer therapy.

Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents

Utilizing scaffold-hopping drug-design strategy, we sought to identify a backup drug candidate for BPR0L075 (1), an indole-based anticancer agent. For this purpose, 5,6-fused bicyclic heteroaromatic scaffolds were designed and synthesized through shufflin